TaiMed Biologics Inc. (TPEX:4147)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
58.00
+1.50 (2.65%)
Jul 30, 2026, 9:46 AM CST

TaiMed Biologics Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-125.62-167.78-201.83-194.81-269.29-470.93
Depreciation & Amortization
150.58150.47150.1150.67151.73152.13
Other Amortization
3.153.144.184.724.724.53
Loss (Gain) From Sale of Assets
1.581.612.32--24.18
Loss (Gain) From Sale of Investments
0.410.69-29.05122.81-26.76
Stock-Based Compensation
8.718.7725.3610.5112.2710.22
Other Operating Activities
63.280.6880.785.82168.85101.38
Change in Accounts Receivable
5.4723.9557.47-62.2459.5497.94
Change in Inventory
6089.44185.47110.85-382.8414.84
Change in Accounts Payable
7.9580.25-12.7413.41-122.49116.79
Change in Unearned Revenue
-71.81-79.01-113.31-27.93-339.16113.91
Change in Other Net Operating Assets
-3.24-1.06-557.36-65.64-11.33-349.5
Operating Cash Flow
100.37191.14-379.55-25.6-605.21-211.28
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-22.7-22.67-8.06-6.15-3.56-9.69
Sale of Property, Plant & Equipment
-----0.41
Sale (Purchase) of Intangibles
-0.1-0.1-11.3--1.21-3.87
Investment in Securities
115.23176.7-695.39-12.88110.88204.07
Other Investing Activities
-0.430.09-0.12.58--
Investing Cash Flow
92154.02-714.84-16.46106.12190.92

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
----200-
Total Debt Issued
----200-
Short-Term Debt Repaid
---200---
Long-Term Debt Repaid
--29.5-28.98-16.05-1.98-1.93
Total Debt Repaid
-29.66-29.5-228.98-16.05-1.98-1.93
Net Debt Issued (Repaid)
-29.66-29.5-228.98-16.05198.02-1.93
Issuance of Common Stock
5.998.781,64535.2810.314.71
Other Financing Activities
-0.92-0.92-4.27-0.050.01
Financing Cash Flow
-103.41-21.641,41219.23208.382.79

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-4.19-5.3711.54-0.2813.21-2.9
Net Cash Flow
84.77318.15329.22-23.1-277.51-20.47

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
77.67168.48-387.61-31.75-608.77-220.96
Free Cash Flow Growth
------
Free Cash Flow Margin
12.92%27.56%-63.52%-6.46%-108.13%-53.44%
Free Cash Flow Per Share
0.280.62-1.45-0.13-2.41-0.88
Levered Free Cash Flow
205.83316.45-268.4782.39-217.42-191.55
Unlevered Free Cash Flow
212.43323.14-260.5991.65-211.11-186.9

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
10.5810.7412.7114.769.887.44
Change in Working Capital
-1.63113.57-440.47-31.56-796.29-6.02